GRATATE MULTI-STATE formulae as a precursor to the receipt of radiopharmaceuticals. (Q79932): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): Currently, in the world, the DOTATATE peptide, the synthetic angomastat, radiolabelled, such as 68Ga, 90Y, or 177LU, is used for diagnostic and isotopic therapies of neuroenteral tumours demonstrating high expression of somatostat receptors.Each of these radioisotopes is obtained by means of chemical separation from home 90Sr, LU-177 may be obtained in a nuclear reactor both as and without support, GA-68 is obtained from so-called radionuclide g...) |
||
| Property / summary | |||
Currently, in the world, the DOTATATE peptide, the synthetic angomastat, radiolabelled, such as 68Ga, 90Y, or 177LU, is used for diagnostic and isotopic therapies of neuroenteral tumours demonstrating high expression of somatostat receptors.Each of these radioisotopes is obtained by means of chemical separation from home 90Sr, LU-177 may be obtained in a nuclear reactor both as and without support, GA-68 is obtained from so-called radionuclide generators 68Ge/68Ga but a number of technical solutions applied in commercial generators make GA-68 obtained in volatile acid solutions.On the other hand, the macrocyclical valley of the DOTATATE peptide is sensitive to the conditions of labelling, the appropriate activity, the chemical purity and the presence of excipients.The aim of the project is to develop the different pharmaceutical formularies of DOTATATE, in the form of dry kits containing peptides and excipients, in order to improve the process of preparing the appropriate radiopharmaceuticals directly at the user (in a healthcare facility) for the patient individually.The project corresponds to the demand of national nuclear medicine and foreign customers and falls within the framework of a modern approach to personalised medicine. (English) | |||
| Property / summary: Currently, in the world, the DOTATATE peptide, the synthetic angomastat, radiolabelled, such as 68Ga, 90Y, or 177LU, is used for diagnostic and isotopic therapies of neuroenteral tumours demonstrating high expression of somatostat receptors.Each of these radioisotopes is obtained by means of chemical separation from home 90Sr, LU-177 may be obtained in a nuclear reactor both as and without support, GA-68 is obtained from so-called radionuclide generators 68Ge/68Ga but a number of technical solutions applied in commercial generators make GA-68 obtained in volatile acid solutions.On the other hand, the macrocyclical valley of the DOTATATE peptide is sensitive to the conditions of labelling, the appropriate activity, the chemical purity and the presence of excipients.The aim of the project is to develop the different pharmaceutical formularies of DOTATATE, in the form of dry kits containing peptides and excipients, in order to improve the process of preparing the appropriate radiopharmaceuticals directly at the user (in a healthcare facility) for the patient individually.The project corresponds to the demand of national nuclear medicine and foreign customers and falls within the framework of a modern approach to personalised medicine. (English) / rank | |||
Normal rank | |||
Revision as of 08:53, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | GRATATE MULTI-STATE formulae as a precursor to the receipt of radiopharmaceuticals. |
Project in Poland financed by DG Regio |
Statements
2,293,216.26 zloty
0 references
3,942,833.58 zloty
0 references
58.16 percent
0 references
1 April 2017
0 references
31 March 2020
0 references
NARODOWE CENTRUM BADAŃ JĄDROWYCH OŚRODEK RADIOIZOTOPÓW POLATOM
0 references
52°32'46.3"N, 21°12'26.3"E
0 references
Obecnie w świecie peptyd DOTATATE, syntetyczny analog somatostatyny znakowany izotopami takimi jak 68Ga, 90Y, czy 177Lu, jest stosowany w diagnostyce i terapii izotopowej guzów neuroendokrynnych wykazujących wysoką ekspresję receptorów somatostatyny. Każdy z wymienionych radioizotopów jest otrzymywany w inny sposób – 90Y jest otrzymywany w wyniku chemicznego rozdziału od macierzystego 90Sr, Lu-177 może być otrzymywany w reaktorze jądrowym zarówno w postaci nośnikowej jak i beznośnikowej, Ga-68 otrzymuje się z tzw. generatorów radionuklidowych 68Ge/68Ga ale liczne rozwiązania techniczne stosowane w komercyjnych generatorach powodują, że Ga-68 otrzymywany w roztworach o zmiennej kwasowości. Z drugiej strony chelat makrocykliczny DOTA występujący w peptydzie DOTATATE jest wrażliwy na warunki znakowania, aktywność właściwą, czystość chemiczną i obecność substancji pomocniczych. Celem projektu jest opracowanie różnych formulacji farmaceutycznych peptydu DOTATATE, w postaci suchych zestawów zawierających peptyd i substancje pomocnicze, w celu usprawnienia procesu przygotowania odpowiednich radiofarmaceutyków bezpośrednio u użytkownika (w placówce służby zdrowia) dla indywidulanego pacjenta. Projekt odpowiada zapotrzebowaniu krajowej medycyny nuklearnej i odbiorców zagranicznych i mieści się w ramach nowoczesnego podejścia do medycyny spersonalizowanej. (Polish)
0 references
Currently, in the world, the DOTATATE peptide, the synthetic angomastat, radiolabelled, such as 68Ga, 90Y, or 177LU, is used for diagnostic and isotopic therapies of neuroenteral tumours demonstrating high expression of somatostat receptors.Each of these radioisotopes is obtained by means of chemical separation from home 90Sr, LU-177 may be obtained in a nuclear reactor both as and without support, GA-68 is obtained from so-called radionuclide generators 68Ge/68Ga but a number of technical solutions applied in commercial generators make GA-68 obtained in volatile acid solutions.On the other hand, the macrocyclical valley of the DOTATATE peptide is sensitive to the conditions of labelling, the appropriate activity, the chemical purity and the presence of excipients.The aim of the project is to develop the different pharmaceutical formularies of DOTATATE, in the form of dry kits containing peptides and excipients, in order to improve the process of preparing the appropriate radiopharmaceuticals directly at the user (in a healthcare facility) for the patient individually.The project corresponds to the demand of national nuclear medicine and foreign customers and falls within the framework of a modern approach to personalised medicine. (English)
0 references
Identifiers
POIR.01.02.00-00-0041/15
0 references